V 3526

Drug Profile

V 3526

Alternative Names: V3526; VEE 3526; VEE IA/B V3526; Venezuelan equine encephalitis virus vaccine - DynPort

Latest Information Update: 30 Dec 2013

Price : $50

At a glance

  • Originator United States Army Medical Research Institute of Infectious Diseases; University of North Carolina at Chapel Hill
  • Developer DynPort Vaccine Company; Northwest Kinetics
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Encephalitis virus infections

Most Recent Events

  • 30 Dec 2013 No development reported - Preclinical for Encephalitis virus infections in USA (SC)
  • 31 Oct 2006 Northwest Kinetics has been acquired by Charles River Laboratories
  • 27 Mar 2006 Dynport and Northwest Kinetics have initiated a phase I trial for Encephalitis virus infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top